Q3 2025 eXoZymes Inc Earnings Call Transcript

Nov 13, 2025 / 10:00 PM GMT

Release Date Price: $16.4 (-0.61%)

Transcript 10-Q

Key Points

Positve

EXoZymes Inc (EXOZ) has successfully developed a proprietary method to produce NCT with a yield of over 90%, unlocking significant market opportunities in both nutraceutical and pharmaceutical sectors.
The company has identified three promising business opportunities: NCT, non-intoxicating cannabinoids, and Sandele, each with substantial market potential and unique value propositions.
EXoZymes Inc (EXOZ) has received a $3 million grant from the National Science Foundation to develop a biosolution for Sandele, demonstrating external validation and financial support for its projects.
The company operates a capital-efficient model, minimizing capital expenditure by leveraging existing infrastructure for production, which reduces the need for significant CapEx investments.
EXoZymes Inc (EXOZ) has a strong pipeline of potential partnerships and joint ventures, particularly in the NCT and cannabinoid spaces, indicating robust interest and potential for future growth.

Negative

EXoZymes Inc (EXOZ) reported a net loss of $2.29 million for the third quarter, with a year-to-date net loss of $6.5 million, highlighting ongoing financial challenges.
The company faces risks related to regulatory approvals, manufacturing scale-up, market adoption rates, and intellectual property, which could impact future success.
There is uncertainty regarding the timing and amount of future capital raises, which could affect the company's ability to fund ongoing operations and growth initiatives.
The company's website and public-facing materials are outdated, potentially impacting investor perception and engagement.
EXoZymes Inc (EXOZ) is still in the pre-commercial phase, meaning it has not yet generated revenue from its products, which could pose a risk to its financial stability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EXOZ.OQ - eXoZymes Inc
Q3 2025 eXoZymes Inc Earnings Call
Nov 13, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ment s Please read our ACC filings to better understand exercise as a business, our risk factors as and as an investment opportunity.

And with that, welcome to our Q3 update. My name is Lesa Garlis. I'm the VP of communications and Investor relations, and I would like to.

To be excited about this call today like I am and we'll go on. This is the agenda for today.

Slightly different format. Our CEO Michael will touch upon that, and I'll give the word to him.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Slightly different format than last time we have an extra sea

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.